Navigation Links
Consortium seeks best treatment for HIV-positive cancer patients
Date:6/7/2010

Washington, DC Preliminary findings from a unique study with sunitinib suggest that it might be possible to tweak the dosage of chemotherapy drugs used to treat HIV-positive cancer patients to achieve therapeutic benefit. Given the type of drug cocktail patients use to treat their HIV, much more or considerably less chemotherapy may be warranted, say the researchers, part of the NCI-supported AIDS Malignancy Consortium (AMC). The trial design is being presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).

Researchers say the early analysis is important because it highlights the Catch 22 that many HIV-infected cancer patients face. "Cancer unrelated to AIDS is rapidly increasing in HIV-positive patients, yet many oncologists do not know how to treat these cancers, and these patients are also excluded from cancer clinical trials," says the study's lead investigator, John F. Deeken, M.D., a medical oncologist at Georgetown Lombardi Comprehensive Cancer Center.

"While such caution is understandable, it may be scientifically unjustified as well as fundamentally unfair, and this study is designed to help guide treatment for these patients," says Deeken, who will present updated data on June 7 during the Trials in Progress Poster Session ASCO.

For reasons that are unclear, cancers that are unrelated to HIV infection are growing at an alarming rate in these patients, compared to the general HIV-negative population, he says. These non-AIDS-defining cancers are also more aggressive, occur at younger ages, have higher rates of relapse and poorer outcomes, Deeken says. For example, HIV patients are 13-31 times more likely to develop Hodgkin's lymphoma, they have a seven times higher rate of developing liver cancer, and three times the rate of developing lung or head and neck cancers, he says.

"A key challenge in treating these patients is that anti-HIV medicines are notorious for causing drug-dru
'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests
2. Three Security Firms Create Consortium To Automate Meaningful Use Requirements And Qualify Clients For $Billions In Stimulus Funds
3. Texas-based consortium announces groundbreaking vaccine research program
4. Regional Radiology Groups Form a National Consortium
5. MIT's Center for Transportation & Logistics Announces new Environmental Performance Consortium at Annual Crossroads Conference
6. The Security Consortium Announces Support for White House Cyber Chief Schmidt
7. University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources
8. University HealthSystem Consortium and ECRI Institute(R) to Provide Enhanced Health Technology Assessment Services
9. RAPS Seeks Nominations for Regulatory Awards, RAPS Fellows
10. Day Twenty-Eight Seeks Krauss For 'Shelter': Film will Personalize Epidemic of Teen Pregnancy
11. European collaboration seeks to create World Wide Web for robots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... time online has the potential to ward off depression ... to research published online in The Journals ... . In the article " Internet Use and ... A Longitudinal Analysis ," the authors report that Internet ... 33 percent among their study sample. , Late-life ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2
... of the wars in Afghanistan and Iraq, studies have shown that ... low, and a Harvard researcher credits the drop, in part, to ... those who do develop the disorder receive the best treatment available. ... issue of Science , Professor of Psychology Richard J. McNally ...
... most of the research on diet and obesity focuses on what ... should be given to when people eat. U.S. researchers ... a day ate as much as mice that were allowed to eat ... with the restricted eating hours gained less weight, had healthier livers and ...
... (HealthDay News) -- Smoking rates among American teens and young ... them still light up, a new federal government report reveals. ... decreased from nearly 12 percent in 2004 to about 8 ... about 34 percent among young adults, according to the analysis ...
... the XIAP protein result in a serious immune malfunction. ... to activate vital components of the immune system. Their ... , a journal of international scientific repute. Researchers ... at the University of Copenhagen have mapped how the ...
... known for years that when the proteins RalA and RalB ... cancer. However, until this week, no study had explored the ... step on the path to developing drugs to target these ... in prostate cancer, to shortened survival in squamous cell carcinoma, ...
... -- Mental distractions can act as a form of pain ... asked to complete a difficult or easy memory task while ... The participants perceived less pain when they were more distracted ... functional MRI, the German researchers also found that the lower ...
Cached Medicine News:Health News:Preventing post-traumatic stress 2Health News:Preventing post-traumatic stress 3Health News:It's Not Just What You Eat, It's When You Eat, Mouse Study Finds 2Health News:Fewer Young Americans Smoking, Survey Finds 2Health News:Scientists study serious immune malfunction 2Health News:Protein RAL associated with aggressive characteristics in prostate, bladder and skin cancers 2
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
... MALVERN, Pa., Feb. 21, 2011 Today, Siemens (NYSE: ... Overhage, MD, PhD, as Chief Medical Informatics Officer (CMIO), of ... of the In diana Health Information Exchange ... this not-for-profit organization. In his role at Siemens, Marc will ...
Cached Medicine Technology:Siemens Appoints Overhage as New Chief Medical Informatics Officer 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: